Search - tctmd.com

Displaying 641 - 660 of 1558

Sort: Relevancy | Date

Presentation TCT 2021

CHOICE-CLOSURE: A Randomized Trial of Plug-Based Versus Suture-Based Large-Bore Vascular Closure

Presenter: Mohamed Abdel-Wahab

November 05, 2021

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

Presentation TCT 2021

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Presenter: Nicolas Van Mieghem

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Presenter: Ori Ben-Yehuda

November 05, 2021

Presentation TCT 2021

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

Presenter: Joanna Chikwe

November 05, 2021

Presentation TCT 2021

FFR REACT: A Randomized Trial of FFR-Guided PCI Optimization by IVUS Versus No Optimization

Presenter: Joost Daemen

November 05, 2021

Presentation TCT 2021

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Presenter: David E. Kandzari

November 04, 2021

Presentation TCT 2021

Triluminate Registry: Lessons Learned for TEER Trial Design

Presenter: Georg Nickenig

November 04, 2021

Presentation TCT 2021

Pragmatic Clinical Trials: The Future is Now?

Presenter: Sreekanth Vemulapalli

November 04, 2021

Presentation TCT 2021

iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI

Presenter: Matthias Götberg

November 04, 2021

Presentation TCT 2021

Adapting Clinical Trials to a Black Swan Event, from Industry Perspective

Presenter: Sandeep Brar

November 04, 2021

Presentation TCT 2021

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Presenter: Ajay Kirtane

November 04, 2021

Presentation TCT 2021

Adapting Clinical Trials to a Black Swan Event, from the FDA Perspective

Presenter: Andrew Farb

November 04, 2021

Presentation TCT 2021

EROSION III: A Randomized Trial of OCT-Guided Intervention in STEMI Patients With Early Infarct Artery Patency

Presenter: Haibo Jia

November 04, 2021

Presentation TCT 2021

SUGAR: A Randomized Trial of Amphilimus-eluting Stents and Zotarolimus-eluting Stents in Patients With Diabetes

Presenter: Rafael Romaguera

November 04, 2021

Presentation TCT 2021

FAVOR III China: A Sham-Controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI

Presenter: Bo Xu

November 04, 2021

Presentation TCT 2021

FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG

Presenter: William Fearon

November 04, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

Presentation TCT 2021

Prasugrel De-escalation Therapy After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Subgroup Analysis of the HOST-REDUCE-POLYTECH-ACS Randomized Clinical Trial

Presenter: Doyeon Hwang

November 04, 2021

Presentation TCT 2021

Debate 2: Pro – The ISCHEMIA Trial Results Do Not Apply to CABG; Our Outcomes Are Different!

Presenter: Mario Gaudino

November 04, 2021

Advertisement

CHOICE-CLOSURE: A Randomized Trial of Plug-Based Versus Suture-Based Large-Bore Vascular Closure

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

SURTAVI: Five-Year Results From a Randomized Trial of TAVR vs. SAVR in Patients at Intermediate Surgical Risk

Perspectives on TEER Trials in Secondary MR (Control Groups, Enrollment Issues, and More)

Perspectives on TEER Trials in Primary MR: From Prohibitive to Intermediate and Low Risk

FFR REACT: A Randomized Trial of FFR-Guided PCI Optimization by IVUS Versus No Optimization

The SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation): Clinical Trials Status Update

Triluminate Registry: Lessons Learned for TEER Trial Design

Pragmatic Clinical Trials: The Future is Now?

iFR-SWEDEHEART: Five-Year Outcomes of a Randomized Trial of iFR-Guided vs. FFR-Guided PCI

Adapting Clinical Trials to a Black Swan Event, from Industry Perspective

RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration

Adapting Clinical Trials to a Black Swan Event, from the FDA Perspective

EROSION III: A Randomized Trial of OCT-Guided Intervention in STEMI Patients With Early Infarct Artery Patency

SUGAR: A Randomized Trial of Amphilimus-eluting Stents and Zotarolimus-eluting Stents in Patients With Diabetes

FAVOR III China: A Sham-Controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI

FAME 3: A Randomized Trial of FFR-Guided Stenting Compared With CABG

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Prasugrel De-escalation Therapy After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Subgroup Analysis of the HOST-REDUCE-POLYTECH-ACS Randomized Clinical Trial

Debate 2: Pro – The ISCHEMIA Trial Results Do Not Apply to CABG; Our Outcomes Are Different!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content